Medivation takes up $335 million Curetech licensing option
– The agreement gives Medivation the license to develop and commercialize Curetech’s pidilizumab cancer treatment. – Medivation has decided to exercise the option granted it by Curetech More...
Investor files class action on Andromeda biotech
– Investor Mori Arkin: If Hyperion overlooked weak points in the data, it’s their mistake. – The Andromeda affair, in which an Israeli company is being accused of forging clinical More...
Len Blavatnik donates $20 million to Tel Aviv University
– The donation will fund drug development, computer science, cyber research, movie production and more. – The Blavatnik Family Foundation is donating $20 million to Tel Aviv University More...
Novartis abandons plans to buy Israeli stem cell treatment company Gamida Cell
– Novartis had signed an MOU to acquire the stem cell treatment company for up to $600 million. – Elbit Medical Technologies Ltd. (TASE:EMTC) and Clal Biotechnology Industries Ltd. (TASE: CBI) More...
Israeli Mediwound Begins Trading On Nasdaq
– The burns and wounds treatment developer is issuing 5 million shares at $14 each. – – Burns and wounds treatment developer Mediwound will begin trading on the US Nasdaq market today. Clal More...
Novartis In Advanced Talks to Acquire Israeli Stem Cell Developer Gamida-Cell
– The stem cell developer could be acquired at a company value of hundreds of millions of dollars. – Stem cell therapies developer Gamida-Cell Ltd. has received an acquisition offer from an international pharma More...
Clal Biotech Selling Diabetes Treatment Co Andromeda
– Clal Biotechnology Industries Ltd. (TASE: CBI) has signed a non-binding letter of intent to sell diabetes treatment developer Andromeda Biotech Ltd. to a US pharmaceutical company for an immediate More...
Teva Sells Andromeda Diabetes Treatment Stake For $72 Million
– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1 Diabetes. – Clal Biotechnology Industries Ltd. (TASE: CBI) More...
More Israeli Life Sciences Companies Going To Nasdaq
– The burn and wound treatment company MediWound plans to raise $100m on Nasdaq at a $400 million valuation. – In the coming weeks, several Israeli life sciences companies will examine whether More...
Len Blavatnik to delist Clal Industries from the Tel Aviv Stock Exchange (TASE)
– Blavatnik’s Access Industries, which owns 49.9% of Clal Industries, will buy the public’s holdings under an offer to purchase. – – / By Efrat Peretz and Kobi Yeshayahou More...